Compare Stocks → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:BLPHNASDAQ:INNTNASDAQ:JAGXNASDAQ:ONCYOTCMKTS:SEOVF Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLPHBellerophon Therapeutics$0.05$0.05$0.03▼$11.15$662K0.6761,081 shs47,040 shsINNTInnovate Biopharmaceuticals$0.97$0.37▼$1.67$8K-0.39525,982 shsN/AJAGXJaguar Health$0.17$0.09$0.05▼$1.22$46.93M1.3551.07 million shs33.93 million shsONCYOncolytics Biotech$1.06$1.07$0.88▼$3.39$79.95M1.93369,956 shs61,862 shsSEOVFSernova$0.32-2.2%$0.41$0.29▼$0.83$96.45M1.1619,451 shs12,605 shsElon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLPHBellerophon Therapeutics+14.68%+7.52%+6.55%+1.03%-99.32%INNTInnovate Biopharmaceuticals0.00%0.00%0.00%0.00%-99.91%JAGXJaguar Health-6.61%-5.78%+133.66%+63.58%-69.84%ONCYOncolytics Biotech+1.92%-1.85%+6.00%-11.67%-6.19%SEOVFSernova-1.54%-5.02%-23.03%-26.09%-48.04%top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (Ad)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution…MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBLPHBellerophon Therapeutics2.1105 of 5 stars3.00.00.04.83.20.00.6INNTInnovate BiopharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AJAGXJaguar HealthN/AN/AN/AN/AN/AN/AN/AN/AONCYOncolytics Biotech0.8143 of 5 stars3.53.00.00.00.60.00.0SEOVFSernovaN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBLPHBellerophon Therapeutics2.00Hold$2.003,596.86% UpsideINNTInnovate BiopharmaceuticalsN/AN/AN/AN/AJAGXJaguar HealthN/AN/AN/AN/AONCYOncolytics Biotech3.00Buy$4.00277.36% UpsideSEOVFSernova2.00Hold$1.50371.85% UpsideCurrent Analyst RatingsLatest JAGX, INNT, BLPH, SEOVF, and ONCY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/4/2024ONCYOncolytics BiotechRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$3.004/4/2024SEOVFSernovaRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageMarket Perform$1.502/14/2024ONCYOncolytics BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBLPHBellerophon Therapeutics$5.64M0.12N/AN/A$0.27 per share0.20INNTInnovate BiopharmaceuticalsN/AN/AN/AN/A($0.27) per shareN/AJAGXJaguar Health$9.76M4.81N/AN/A$0.07 per share2.43ONCYOncolytics BiotechN/AN/AN/AN/A$0.27 per shareN/ASEOVFSernovaN/AN/AN/AN/A$0.03 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBLPHBellerophon Therapeutics-$19.83M-$0.84N/A∞N/AN/A-187.35%-104.97%5/13/2024 (Estimated)INNTInnovate Biopharmaceuticals-$27.05MN/AN/AN/AN/AN/AN/A-234.42%N/AJAGXJaguar Health-$41.30MN/A0.00∞N/A-423.11%-837.11%-80.76%5/20/2024 (Estimated)ONCYOncolytics Biotech-$20.56M-$0.30N/AN/AN/AN/A-105.97%-72.80%5/3/2024 (Estimated)SEOVFSernova-$28.91M-$0.09N/A∞N/AN/A-226.64%-145.26%6/12/2024 (Estimated)Latest JAGX, INNT, BLPH, SEOVF, and ONCY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/18/2024Q1 2024SEOVFSernovaN/A-$0.02-$0.02-$0.02N/AN/A3/7/2024Q4 2023ONCYOncolytics Biotech-$0.11-$0.04+$0.07-$0.04N/AN/A1/29/2024Q4 2023SEOVFSernovaN/A-$0.03-$0.03-$0.03N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBLPHBellerophon TherapeuticsN/AN/AN/AN/AN/AINNTInnovate BiopharmaceuticalsN/AN/AN/AN/AN/AJAGXJaguar HealthN/AN/AN/AN/AN/AONCYOncolytics BiotechN/AN/AN/AN/AN/ASEOVFSernovaN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBLPHBellerophon TherapeuticsN/A3.963.96INNTInnovate BiopharmaceuticalsN/A0.350.35JAGXJaguar Health6.332.001.34ONCYOncolytics BiotechN/A9.019.01SEOVFSernova0.141.201.20OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBLPHBellerophon Therapeutics10.61%INNTInnovate Biopharmaceuticals5.88%JAGXJaguar Health12.04%ONCYOncolytics Biotech6.82%SEOVFSernovaN/AInsider OwnershipCompanyInsider OwnershipBLPHBellerophon Therapeutics5.20%INNTInnovate Biopharmaceuticals7.90%JAGXJaguar Health0.02%ONCYOncolytics Biotech0.10%SEOVFSernovaN/AMiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableBLPHBellerophon Therapeutics1812.23 million11.60 millionNo DataINNTInnovate Biopharmaceuticals841.33 millionN/ANot OptionableJAGXJaguar Health49276.22 million276.16 millionNo DataONCYOncolytics Biotech2975.42 million75.35 millionNot OptionableSEOVFSernovaN/A303.41 millionN/ANot OptionableJAGX, INNT, BLPH, SEOVF, and ONCY HeadlinesSourceHeadlineSernova Names Nicholas Rossettos Interim CFOmarketwatch.com - March 11 at 1:39 PMSernova reports anticipated 2024 milestonesmsn.com - January 29 at 10:40 AMSernova gets FDA orphan drug, rare pediatric designations for hemophilia Amsn.com - November 27 at 8:15 PMClosing Bell: Sernova Corp flat on Tuesday (SVA)theglobeandmail.com - November 14 at 9:04 PMSernova Announces New Advancements of Conformal Coating Technology in Combination with the Cell Pouch System™ at the 2023 IPITA-IXA-CTRMS Joint Congressfinance.yahoo.com - October 30 at 7:35 AMSernova Presents Compelling New Data on the Cell Pouch System™ as a Promising Treatment for Post-Operative Hypothyroidism at the 2023 American Thyroid Association Annual Meetingfinance.yahoo.com - September 29 at 1:00 PMSernova Provides Development Update on Proprietary Cellular Conformal Coating Technology in Combination with Cell Pouch Devicefinance.yahoo.com - September 7 at 10:11 AMSernova Appoints Cynthia Pussinen as Chief Executivemarketwatch.com - September 5 at 4:32 PMSernova appoints CEOseekingalpha.com - September 5 at 4:32 PMSernova reports positive interim data for Cell Pouch Systemmassdevice.com - June 26 at 6:49 PMSernova (SVA) Receives a Buy from H.C. Wainwrightmarkets.businessinsider.com - June 26 at 8:00 AMSernova to Present Updated Interim Phase 1/2 Clinical Data on Cell Pouch System™ During Oral Presentation at American Diabetes Association 83rd Scientific Sessionsfinance.yahoo.com - June 22 at 6:01 PMSernova is significantly undervalued, says Echeloncantechletter.com - June 16 at 11:36 PMSernova to Participate in Upcoming Truist Securities Cell Therapy Symposiumfinance.yahoo.com - June 16 at 1:35 PMEchelon Wealth Partners Remains a Buy on Sernova (SVA)markets.businessinsider.com - June 15 at 3:50 PMSernova Announces Executive Alignment and Appoints New Board Chairfinance.yahoo.com - May 31 at 8:58 AMClosing Bell: Sernova Corp flat on Monday (SVA)theglobeandmail.com - May 8 at 9:43 PMSernova Corp. Announces Voting Results of the 2023 Annual General Meeting of Shareholdersthenewswire.com - April 28 at 3:38 PMClosing Bell: Sernova Corp flat on Thursday (SVA)theglobeandmail.com - April 28 at 10:37 AMConcerned Shareholders of Sernova Corp. Wish to Thank All Shareholdersfinance.yahoo.com - April 25 at 6:02 PMSernova Reminds Shareholders to Vote FOR the Eight Management Director Nominees Using ONLY the WHITE Management Proxythenewswire.com - April 21 at 12:40 PMProxy adviser backs diabetes device developer Sernova in fight against activist investorsmedtechdive.com - April 17 at 3:33 PMSernova to Present at 2023 Alliance for Regenerative Medicine Cell & Gene Meeting on the Medfinance.yahoo.com - April 10 at 8:20 AMSernova defends record after investors attack ‘sluggish’ progress of regenerative medicine implantmedtechdive.com - April 7 at 3:12 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsBellerophon TherapeuticsNASDAQ:BLPHBellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse, which is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.Innovate BiopharmaceuticalsNASDAQ:INNTInnovate Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company's lead product candidate is INN-202 that has completed Phase IIb clinical trial for the treatment of celiac disease. It also develops INN-108, which has completed Phase I clinical trial to treat mild-to-moderate ulcerative colitis; INN-217 for the treatment of non-alcoholic steatohepatitis and microbiome; and INN-289 to treat crohn's disease, as well as product for the treatment of alcoholic steatohepatitis (ASH). In addition, the company holds rights for INN-329, a formulation of secretin that is used to enhance visualization in magnetic resonance cholangiopancreatography procedures that is in Phase III clinical trial. The company has a research collaboration with Massachusetts General Hospital for the treatment of ASH. Innovate Biopharmaceuticals, Inc. is based in Raleigh, North Carolina.Jaguar HealthNASDAQ:JAGXJaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including Short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops NP-300, a second-generation proprietary anti-secretory antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. The company was founded in 2013 and is headquartered in San Francisco, California.Oncolytics BiotechNASDAQ:ONCYOncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.SernovaOTCMKTS:SEOVFSernova Corp. operates as a clinical-stage regenerative medicine therapeutics company in Canada. The company focuses on the development and commercialization of regenerative medicine therapeutics, including its proprietary Cell Pouch and associated technologies consisting of therapeutic cells and local cellular immune protection. Its Cell Pouch is a novel implantable and scalable medical device which forms a natural environment in the body for the housing and long-term survival and function of therapeutic cells, which release necessary proteins or factors missing from the body to treat chronic diseases as an alternative to daily administration of drugs. Sernova Corp. has a research agreement with the University of Miami to advance the development of Conformal Coating Technology in combination with therapeutic cells within Cell Pouch. Sernova Corp. was incorporated in 1998 and is headquartered in London, Canada. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.